Gary H. Lyman, MD, MPH
Department / Division
Medicine /
Medicine - Oncology
Address
P.O. Box 2736
Durham, NC 27705
Appointment Telephone
919-660-9672
Office Telephone
919-681-1604
Fax Telephone
919-681-7488
- MD, University at Buffalo State University of New York School of Medicine & Biomedical Sciences, 1972
- Internal Medicine, UNC Hospitals, 1972-1974
- Hematology-Oncology, Roswell Park Memorial Institute (New York), 1975-1977
- MPH, Biostatistics, Harvard University (Massachusetts), 1982
Clinical Interests
Clinical investigation; experimental therapeutics; breast cancer; care of patients with breast cancer, with a focus on managing early-stage patients for staging/prognostic evaluation and clinical decision making; comparative effectiveness and outcomes research
Research Interests
Dr. Gary Lyman is Professor of Medicine in the Division of Medical Oncology, Department of Internal Medicine at Duke University School of Medicine and the Duke Cancer Institute. He serves as Director of the Comparative Effectiveness and Outcomes Research Program in Oncology. Dr Lyman is also Senior Fellow in the Duke Center for Clinical Health Policy Research. He is a nationally and internationally recognized authority on comparative effectiveness and health services and outcomes research. Lyman research is funded by the National Cancer Institute, the National Heart Lung and Blood Institute, the American Society of Clinical Oncology along with industry grants related to supportive cancer care. Dr Lyman has published some 400 research articles in in the professional medical literature. Direct funding from all sources supports an annual Comparative Effectiveness and Outcomes Research budget of over $5 million.
Dr Lyman’s research interests include:
Personalized Medicine and Cancer Supportive Care: In addition to the conduct of randomized controlled trials of new cancer diagnostic, prognostic, treatment and supportive care approaches, Dr Lyman’s research interests include the personalized management of early-stage breast cancer and supportive care of patients receiving cancer chemotherapy, most notably those at risk for febrile neutropenia and venous thromboembolism. Based on clinical trial results, Dr Lyman is actively involved in the development and validation of clinical risk models for patient selection and targeted intervention and preventive strategies. Dr Lyman is co-PI on an NCI on comparative effectiveness of cancer pharmacogenomics grant to discover and validate new genomic tools for guiding more personalized cancer treatments and on an NHLBI trial of thromboprophylaxis in high risk ambulatory patients receiving cancer chemotherapy.
Evidence synthesis, clinical practice guidelines and health policy: Dr Lyman conducts systematic reviews and meta-analyses of major clinical issues in support of clinical practice guidelines. Dr Lyman chairs several guidelines for the American Society of Clinical Oncology including those on antiemetics, venous thromboembolism, sentinel node biopsy in patients with breast cancer and cutaneous melanoma and on weight based dosing of chemotherapy. Dr Lyman also conducts analyses of large population studies of clinical outcomes associated with of current cancer patient management in a real world setting with a particular focus on cancer management in the elderly patient with cancer. Dr Lyman leads several decision simulation studies for improved clinical decision making and cost-effectiveness analysis of new and novel therapies based on results of clinical trials, systematic reviews and population studies. He serves as an advisor on new oncologic agents to the US FDA. Dr Lyman also serves as Editor-in-Chief of Cancer Investigation and on the editorial boards of several prestigious research journals.
This faculty member has no reported relationships with industry.
Representative Publications
Hanna, RK; Poniewierski, MS; Laskey, RA; Lopez, MA; Shafer, A; Van Le, L; Crawford, J; Dale, DC; Gehrig, PA; Secord, AA; Havrilesky, LJ; Lyman, GH. Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecologic Oncology. 2013;129:74-80.
(2013)
Abstract
Hirsch, BR; Reed, SD; Lyman, GH. Update on the role of epothilones in metastatic breast cancer. Current Breast Cancer Reports. 2013;5:51-56.
(2013)
Lyman, GH; Baker, J; Geradts, J; Horton, J; Kimmick, G; Peppercorn, J; Pruitt, S; Scheri, RP; Hwang, ES. Multidisciplinary care of patients with early-stage breast cancer. Surgical Oncology Clinics of North America. 2013;22:299-317.
(2013)
Abstract
Lyman, GH; Khorana, AA; Kuderer, NM; Lee, AY; Arcelus, JI; Balaban, EP; Clarke, JM; Flowers, CR; Francis, CW; Gates, LE; Kakkar, AK; Key, NS; Levine, MN; Liebman, HA; Tempero, MA; Wong, SL; Prestrud, AA; Falanga, A. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. 2013;
(2013)
Abstract
Nguyen, XV; Roy Choudhury, K; Eastwood, JD; Lyman, GH; Esclamado, RM; Werner, JD; Hoang, JK. Incidental Thyroid Nodules on CT: Evaluation of 2 Risk-Categorization Methods for Work-Up of Nodules. American Journal of Neuroradiology. 2013;
(2013)
Abstract
Rajan, SS; Carpenter, WR; Stearns, SC; Lyman, GH. Short-Term Costs Associated With Primary Prophylactic G-CSF Use During Chemotherapy. American Journal of Managed Care. 2013;19:150-159.
(2013)
Reed, SD; Dinan, MA; Schulman, KA; Lyman, GH. Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genetics in Medicine. 2013;15:203-211.
(2013)
Abstract
Simonds, NI; Khoury, MJ; Schully, SD; Armstrong, K; Cohn, WF; Fenstermacher, DA; Ginsburg, GS; Goddard, KA; Knaus, WA; Lyman, GH; Ramsey, SD; Xu, J; Freedman, AN. Comparative Effectiveness Research in Cancer Genomics and Precision Medicine: Current Landscape and Future Prospects. Journal of National Cancer Institute. 2013;
(2013)
Abstract
Extermann, M; Boler, I; Reich, RR; Lyman, GH; Brown, RH; DeFelice, J; Levine, RM; Lubiner, ET; Reyes, P; Schreiber, FJ; Balducci, L. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118:3377-3386.
(2012)
Abstract
Goddard, KA; Knaus, WA; Whitlock, E; Lyman, GH; Feigelson, HS; Schully, SD; Ramsey, S; Tunis, S; Freedman, AN; Khoury, MJ; Veenstra, DL. Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genetics in Medicine. 2012;14:633-642.
(2012)
Abstract
Griffiths, RI; Barron, RL; Gleeson, ML; Danese, MD; O'Hagan, A; Chia, VM; Legg, JC; Lyman, GH. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer. PharmacoEconomics. 2012;30:103-118.
(2012)
Abstract
Griggs, JJ; Mangu, PB; Anderson, H; Balaban, EP; Dignam, JJ; Hryniuk, WM; Morrison, VA; Pini, TM; Runowicz, CD; Rosner, GL; Shayne, M; Sparreboom, A; Sucheston, LE; Lyman, GH; American Society of Clinical Oncology. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. 2012;30:1553-1561.
(2012)
Abstract
Hirsch, BR; Lyman, GH. Pharmacoeconomics of the myeloid growth factors: a critical and systematic review. PharmacoEconomics. 2012;30:497-511.
(2012)
Abstract
Hornberger, J; Lyman, GH; Chien, R; Meropol, NJ. A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs. Value in Health. 2012;15:1014-1021.
(2012)
Abstract
Hurwitz, HI; Lyman, GH. Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?. Journal of Clinical Oncology. 2012;30:580-581.
(2012)
Abstract
Khorana, AA; Spyropoulos, AC; Zwicker, J; Lyman, GH; Francis, CW. Preventing VTE in Outpatients With Cancer. Chest. 2012;142:265-266.
(2012)
Abstract
Laskey, RA; Poniewierski, MS; Lopez, MA; Hanna, RK; Secord, AA; Gehrig, PA; Lyman, GH; Havrilesky, LJ. Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. Gynecologic Oncology. 2012;125:625-630.
(2012)
Abstract
Loblaw, DA; Prestrud, AA; Somerfield, MR; Oliver, TK; Brouwers, MC; Nam, RK; Lyman, GH; Basch, E; Americal Society of Clinical Oncology Clinical Practice Guidelines. American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. Journal of Clinical Oncology. 2012;30:3136-3140.
(2012)
Abstract
Lyman, GH. The incidence of venous thromboembolism in cancer patients: a real-world analysis. Clinical Advances in Hematology and Oncology. 2012;10:40-42.
(2012)
Abstract
Lyman, GH. Weight-based chemotherapy dosing in obese patients with cancer: back to the future. Journal of Oncology Practice. 2012;8:e62-e64.
(2012)
Abstract
Lyman, GH; Barron, RL; Natoli, JL; Miller, RM. Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. Critical Reviews in Oncology Hematology. 2012;81:296-308.
(2012)
Abstract
Lyman, GH; Burstein, HJ; Buzdar, AU; D'Agostino, R; Ellis, PA. Making genuine progress against metastatic breast cancer. Journal of Clinical Oncology. 2012;30:3448-3451.
(2012)
Abstract
Lyman, GH; Levine, M. Comparative effectiveness research in oncology: an overview. Journal of Clinical Oncology. 2012;30:4181-4184.
(2012)
Abstract
Lyman, GH; Levine, M. Epilogue: the peril and the promise of comparative effectiveness research in oncology. Journal of Clinical Oncology. 2012;30:4282.
(2012)
Abstract
Michels, SL; Barron, RL; Reynolds, MW; Smoyer Tomic, K; Yu, J; Lyman, GH. Costs associated with febrile neutropenia in the US. PharmacoEconomics. 2012;30:809-823.
(2012)
Abstract
Weycker, D; Barron, R; Edelsberg, J; Kartashov, A; Lyman, GH. Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice. Breast Cancer Research and Treatment. 2012;133:301-310.
(2012)
Abstract
Weycker, D; Edelsberg, J; Kartashov, A; Barron, R; Lyman, G. Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. Chemotherapy: international journal of experimental and clinical chemotherapy. 2012;58:8-18.
(2012)
Abstract
Wong, SL; Balch, CM; Hurley, P; Agarwala, SS; Akhurst, TJ; Cochran, A; Cormier, JN; Gorman, M; Kim, TY; McMasters, KM; Noyes, RD; Schuchter, LM; Valsecchi, ME; Weaver, DL; Lyman, GH; American Society of Clinical Oncology, ; Society of Surgical Oncology. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Annals of Surgical Oncology. 2012;19:3313-3324.
(2012)
Abstract
Wong, SL; Balch, CM; Hurley, P; Agarwala, SS; Akhurst, TJ; Cochran, A; Cormier, JN; Gorman, M; Kim, TY; McMasters, KM; Noyes, RD; Schuchter, LM; Valsecchi, ME; Weaver, DL; Lyman, GH; American Society of Clinical Oncology, ; Society of Surgical Oncology. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Journal of Clinical Oncology. 2012;30:2912-2918.
(2012)
Abstract
Aapro, MS; Bohlius, J; Cameron, DA; Dal Lago, L; Donnelly, JP; Kearney, N; Lyman, GH; Pettengell, R; Tjan-Heijnen, VC; Walewski, J; Weber, DC; Zielinski, C; European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. European Journal of Cancer. 2011;47:8-32.
(2011)
Abstract
Basch, E; Hesketh, PJ; Kris, MG; Prestrud, AA; Temin, S; Lyman, GH. Antiemetics: american society of clinical oncology clinical practice guideline update. Journal of Oncology Practice. 2011;7:395-398.
(2011)
Abstract
Basch, E; Prestrud, AA; Hesketh, PJ; Kris, MG; Feyer, PC; Somerfield, MR; Chesney, M; Clark-Snow, RA; Flaherty, AM; Freundlich, B; Morrow, G; Rao, KV; Schwartz, RN; Lyman, GH; American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology. 2011;29:4189-4198.
(2011)
Abstract
Basch, E; Somerfield, MR; Partridge, A; Schnipper, L; Lyman, GH. Commentary: should cost and comparative value of treatments be considered in clinical practice guidelines?. Journal of Oncology Practice. 2011;7:398-401.
(2011)
Abstract
Crawford, J; Allen, J; Armitage, J; Blayney, DW; Cataland, SR; Heaney, ML; Htoy, S; Hudock, S; Kloth, DD; Kuter, DJ; Lyman, GH; McMahon, B; Steensma, DP; Vadhan-Raj, S; Westervelt, P; Westmoreland, M; National Comprehensive Cancer Network. Myeloid growth factors. Journal of the National Comprehensive Cancer Network : JNCCN. 2011;9:914-932.
(2011)
Abstract
Eldar-Lissai, A; Lyman, GH. The economics of the hematopoietic growth factors. Cancer Treatment and Research. 2011;157:403-418.
(2011)
Abstract
Hirsch, BR; Lyman, GH. Biosimilars: are they ready for primetime in the United States?. Journal of the National Comprehensive Cancer Network : JNCCN. 2011;9:934-942.
(2011)
Abstract
Hirsch, BR; Lyman, GH. Breast cancer screening with mammography. Current Oncology Reports. 2011;13:63-70.
(2011)
Abstract
Hurwitz, HI; Saltz, LB; Van Cutsem, E; Cassidy, J; Wiedemann, J; Sirzén, F; Lyman, GH; Rohr, UP. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. Journal of Clinical Oncology. 2011;29:1757-1764.
(2011)
Abstract
Kuderer, NM; Lyman, GH. Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. Journal of National Cancer Institute. 2011;103:910-913.
(2011)
Abstract
Lyman, GH. Commentary: chemotherapy dosing in obese patients with cancer-the need for evidence-based clinical practice guidelines. Journal of Oncology Practice. 2011;7:17-18.
(2011)
Abstract
Lyman, GH. The myeloid growth factors. Cancer Treatment and Research. 2011;157:109-125.
(2011)
Abstract
Lyman, GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer. 2011;117:1334-1349.
(2011)
Abstract
Lyman, GH; Dale, DC. Introduction to the hematopoietic growth factors. Cancer Treatment and Research. 2011;157:3-10.
(2011)
Abstract
Lyman, GH; Dale, DC. Long-term outcomes of myeloid growth factor treatment. Journal of the National Comprehensive Cancer Network : JNCCN. 2011;9:945-952.
(2011)
Abstract
Lyman, GH; Kleiner, JM. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. Cancer Treatment and Research. 2011;157:145-165.
(2011)
Abstract
Lyman, GH; Kuderer, NM. Granulocyte colony-stimulating factors and risk of acute myeloid leukemia and myelodysplastic syndrome. Cancer Treatment and Research. 2011;157:167-178.
(2011)
Abstract
Lyman, GH; Kuderer, NM; Crawford, J; Wolff, DA; Culakova, E; Poniewierski, MS; Dale, DC. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer. 2011;117:1917-1927.
(2011)
Abstract
Rajan, SS; Lyman, GH; Carpenter, WR; Stearns, SC. Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer. Breast Cancer Research and Treatment. 2011;127:511-520.
(2011)
Abstract
Rajan, SS; Lyman, GH; Stearns, SC; Carpenter, WR. Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy. Medical Care. 2011;49:649-657.
(2011)
Abstract
Rajan, SS; Stearns, SC; Lyman, GH; Carpenter, WR. Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients. Breast Cancer Research and Treatment. 2011;130:255-266.
(2011)
Abstract
Valsecchi, ME; Silbermins, D; de Rosa, N; Wong, SL; Lyman, GH. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. Journal of Clinical Oncology. 2011;29:1479-1487.
(2011)
Abstract
Zelenetz, AD; Ahmed, I; Braud, EL; Cross, JD; Davenport-Ennis, N; Dickinson, BD; Goldberg, SE; Gottlieb, S; Johnson, PE; Lyman, GH; Markus, R; Matulonis, UA; Reinke, D; Li, EC; DeMartino, J; Larsen, JK; Hoffman, JM. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. Journal of the National Comprehensive Cancer Network : JNCCN. 2011;9 Suppl 4:S1-22.
(2011)
Abstract
Zeliadt, SB; Sekaran, NK; Hu, EY; Slatore, CC; Au, DH; Backhus, L; Wu, DY; Crawford, J; Lyman, GH; Dale, DC. Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest. Journal of Thoracic Oncology. 2011;6:1726-1732.
(2011)
Abstract
de Rosa, N; Lyman, GH; Silbermins, D; Valsecchi, ME; Pruitt, SK; Tyler, DM; Lee, WT. Sentinel node biopsy for head and neck melanoma: a systematic review. Otolaryngology. 2011;145:375-382.
(2011)
Abstract
Aapro, M; Schwenkglenks, M; Lyman, GH; Lopez Pousa, A; Lawrinson, S; Skacel, T; Bacon, P; von Minckwitz, G. Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Critical Reviews in Oncology Hematology. 2010;74:203-210.
(2010)
Abstract
Connolly, GC; Khorana, AA; Kuderer, NM; Culakova, E; Francis, CW; Lyman, GH. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thrombosis Research. 2010;
(2010)
Abstract
Connolly, GC; Khorana, AA; Kuderer, NM; Culakova, E; Francis, CW; Lyman, GH. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thrombosis Research. 2010;126:113-118.
(2010)
Abstract
Hamilton, EP; Lyman, GH; Peppercorn, J. Availability of experimental therapy outside oncology randomized clinical trials in the United States. Journal of Clinical Oncology. 2010;28:5067-5073.
(2010)
Abstract
Herold, CI; Djulbegovic, B; Hozo, I; Lyman, GH. Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. Breast Cancer Research and Treatment. 2010;121:771-776.
(2010)
Abstract
Lyman, GH. A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia. Current Opinion in Hematology. 2010;
(2010)
Abstract
Lyman, GH. Anthracyclines in the treatment of early-stage breast cancer: ally or adversary?. Cancer Investigation. 2010;28:217-219.
(2010)
Abstract
Lyman, GH. Breast cancer screening: science, society and common sense. Cancer Investigation. 2010;28:1-6.
(2010)
Abstract
Lyman, GH; Dale, DC; Wolff, DA; Culakova, E; Poniewierski, MS; Kuderer, NM; Crawford, J. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. Journal of Clinical Oncology. 2010;28:2914-2924.
(2010)
Abstract
Lyman, GH; Kuderer, NM; American Society of Clinical Oncology. Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines. Thrombosis Research. 2010;125 Suppl 2:S120-S127.
(2010)
Abstract
Lyman, GH; Michels, SL; Reynolds, MW; Barron, R; Tomic, KS; Yu, J. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010;116:5555-5563.
(2010)
Abstract
Lyman, GH; Rolston, KV. How we treat febrile neutropenia in patients receiving cancer chemotherapy. Journal of Oncology Practice. 2010;6:149-152.
(2010)
Abstract
Schwenkglenks, M; Pettengell, R; Szucs, TD; Culakova, E; Lyman, GH. Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery. Journal of Hematology and Oncology. 2010;3:27.
(2010)
Abstract
Tang, P; Wang, J; Hicks, DG; Wang, X; Schiffhauer, L; McMahon, L; Yang, Q; Shayne, M; Huston, A; Skinner, KA; Griggs, J; Lyman, G. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. Cancer Investigation. 2010;28:978-982.
(2010)
Abstract
Bevers, TB; Anderson, BO; Bonaccio, E; Buys, S; Daly, MB; Dempsey, PJ; Farrar, WB; Fleming, I; Garber, JE; Harris, RE; Heerdt, AS; Helvie, M; Huff, JG; Khakpour, N; Khan, SA; Krontiras, H; Lyman, G; Rafferty, E; Shaw, S; Smith, ML; Tsangaris, TN; Williams, C; Yankeelov, T; National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. Journal of the National Comprehensive Cancer Network : JNCCN. 2009;7:1060-1096.
(2009)
Abstract
Cosler, LE; Lyman, GH. Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. Cancer Investigation. 2009;27:953-959.
(2009)
Abstract
Crawford, J; Armitage, J; Balducci, L; Bennett, C; Blayney, DW; Cataland, SR; Dale, DC; Demetri, GD; Erba, HP; Foran, J; Freifeld, AG; Goemann, M; Heaney, ML; Htoy, S; Hudock, S; Kloth, DD; Kuter, DJ; Lyman, GH; Michaud, LB; Miyata, SC; Tallman, MS; Vadhan-Raj, S; Westervelt, P; Wong, MK; National Comprehensive Cancer Network. Myeloid growth factors. Journal of the National Comprehensive Cancer Network : JNCCN. 2009;7:64-83.
(2009)
Abstract
Khorana, AA; Streiff, MB; Farge, D; Mandala, M; Debourdeau, P; Cajfinger, F; Marty, M; Falanga, A; Lyman, GH. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. Journal of Clinical Oncology. 2009;27:4919-4926.
(2009)
Abstract
Kuderer, NM; Lyman, GH. Gene expression profile assays as predictors of distant recurrence-free survival in early-stage breast cancer. Cancer Investigation. 2009;27:885-890.
(2009)
Abstract
Lyman, G; Lalla, A; Barron, R; Dubois, RW. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Current Medical Research and Opinion. 2009;25:401-411.
(2009)
Abstract
Lyman, GH. Comparative effectiveness research in oncology: the need for clarity, transparency and vision. Cancer Investigation. 2009;27:593-597.
(2009)
Abstract
Lyman, GH. Impact of chemotherapy dose intensity on cancer patient outcomes. Journal of the National Comprehensive Cancer Network : JNCCN. 2009;7:99-108.
(2009)
Abstract
Lyman, GH. Preventing venous thromboembolism in cancer patients: can we do better?. Journal of Oncology Practice. 2009;5:165-166.
(2009)
Abstract
Lyman, GH. The road to romiplostim approval and beyond. Oncology. 2009;23:709-715.
(2009)
Abstract
Lyman, GH. Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer. 2009;115:5637-5650.
(2009)
Abstract
Lyman, GH; Khorana, AA. Cancer, clots and consensus: new understanding of an old problem. Journal of Clinical Oncology. 2009;27:4821-4826.
(2009)
Abstract
Lyman, GH; Khorana, AA; Kuderer, NM; Lee, AY. Cancer and thrombosis: back to the future renewed interest in an old problem. Cancer Investigation. 2009;27:472-473.
(2009)
Abstract
Lyman, GH; Kuderer, NM; Freedland, SJ. Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding. Journal of National Cancer Institute. 2009;101:543-545.
(2009)
Abstract
Lyman, GH; Lalla, A; Barron, RL; Dubois, RW. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clinical Therapeutics: the international peer-reviewed journal of drug therapy. 2009;31:1092-1104.
(2009)
Abstract
Lyman, GH; Peppercorn, J. Isolated tumor cells in breast cancer. New England Journal of Medicine. 2009;361:1994.
(2009)
Abstract
Madeb, R; Golijanin, D; Noyes, K; Fisher, S; Stephenson, JJ; Long, SR; Knopf, J; Lyman, GH; Messing, EM. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer. 2009;115:2660-2670.
(2009)
Abstract
Ramsey, SD; Liu, Z; Boer, R; Sullivan, SD; Malin, J; Doan, QV; Dubois, RW; Lyman, GH. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value in Health. 2009;12:217-225.
(2009)
Abstract
Shayne, M; Culakova, E; Wolff, D; Poniewierski, MS; Dale, DC; Crawford, J; Lyman, GH. Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer. 2009;115:5319-5328.
(2009)
Abstract
von Minckwitz, G; Schwenkglenks, M; Skacel, T; Lyman, GH; Pousa, AL; Bacon, P; Easton, V; Aapro, MS. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. European Journal of Cancer. 2009;45:608-617.
(2009)
Abstract
Acharya, CR; Hsu, DS; Anders, CK; Anguiano, A; Salter, KH; Walters, KS; Redman, RC; Tuchman, SA; Moylan, CA; Mukherjee, S; Barry, WT; Dressman, HK; Ginsburg, GS; Marcom, KP; Garman, KS; Lyman, GH; Nevins, JR; Potti, A. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA: Journal of the American Medical Association. 2008;299:1574-1587.
(2008)
Abstract
Constine, LS; Tarbell, N; Hudson, MM; Schwartz, C; Fisher, SG; Muhs, AG; Basu, SK; Kun, LE; Ng, A; Mauch, P; Sandhu, A; Culakova, E; Lyman, G; Mendenhall, N. Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. International Journal of Radiation: Oncology - Biology - Physics. 2008;72:24-33.
(2008)
Abstract
Crawford, J; Dale, DC; Kuderer, NM; Culakova, E; Poniewierski, MS; Wolff, D; Lyman, GH. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. Journal of the National Comprehensive Cancer Network : JNCCN. 2008;6:109-118.
(2008)
Abstract
Eldar-Lissai, A; Cosler, LE; Culakova, E; Lyman, GH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value in Health. 2008;11:172-179.
(2008)
Abstract
Ferro, SA; Myer, BS; Wolff, DA; Poniewierski, MS; Culakova, E; Cosler, LE; Scarpace, SL; Khorana, AA; Lyman, GH. Variation in the cost of medications for the treatment of colorectal cancer. American Journal of Managed Care. 2008;14:717-725.
(2008)
Abstract
Fletcher, JW; Djulbegovic, B; Soares, HP; Siegel, BA; Lowe, VJ; Lyman, GH; Coleman, RE; Wahl, R; Paschold, JC; Avril, N; Einhorn, LH; Suh, WW; Samson, D; Delbeke, D; Gorman, M; Shields, AF. Recommendations on the use of 18F-FDG PET in oncology. Journal of Nuclear Medicine. 2008;49:480-508.
(2008)
Abstract
Greenberg, PL; Cosler, LE; Ferro, SA; Lyman, GH. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. Journal of the National Comprehensive Cancer Network : JNCCN. 2008;6:942-953.
(2008)
Abstract
Hanley, K; Wang, J; Bourne, P; Yang, Q; Gao, AC; Lyman, G; Tang, P. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. Human Pathology. 2008;39:386-392.
(2008)
Abstract
Horan, JT; Alonzo, TA; Lyman, GH; Gerbing, RB; Lange, BJ; Ravindranath, Y; Becton, D; Smith, FO; Woods, WG; Children's Oncology Group. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. Journal of Clinical Oncology. 2008;26:5797-5801.
(2008)
Abstract
Khorana, AA; Francis, CW; Blumberg, N; Culakova, E; Refaai, MA; Lyman, GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Archives of Internal Medicine. 2008;168:2377-2381.
(2008)
Abstract
Khorana, AA; Kuderer, NM; Culakova, E; Lyman, GH; Francis, CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902-4907.
(2008)
Abstract
Lyman, GH. ASCO Clinical Practice Guidelines: Past, Present and Future. Journal of Oncology Practice. 2008;4:236-237.
(2008)
Abstract
Lyman, GH. Caring for the elderly cancer patient: training the next generation of oncologists. Journal of Oncology Practice. 2008;4:193-194.
(2008)
Abstract
Lyman, GH. Undertreatment of cancer patients with chemotherapy is a global concern. Journal of Oncology Practice. 2008;4:114-115.
(2008)
Abstract
Lyman, GH; Hauser, RS. Optimal cancer care across the spectrum of life and disease. American Journal of Managed Care. 2008;14:262-264.
(2008)
Abstract
Somerfield, MR; Einhaus, K; Hagerty, KL; Brouwers, MC; Seidenfeld, J; Lyman, GH; American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges. Journal of Clinical Oncology. 2008;26:4022-4026.
(2008)
Abstract
Blumberg, N; Zhao, H; Wang, H; Messing, S; Heal, JM; Lyman, GH. The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion. 2007;47:573-581.
(2007)
Abstract
Cosler, LE; Eldar-Lissai, A; Culakova, E; Kuderer, NM; Dale, D; Crawford, J; Lyman, GH. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. PharmacoEconomics. 2007;25:343-351.
(2007)
Abstract
Crawford, J; Althaus, B; Armitage, J; Balducci, L; Bennett, C; Blayney, DW; Cataland, SR; Dale, DC; Demetri, GD; Erba, HP; Foran, J; Freifeld, AG; Heaney, ML; Htoy, S; Kloth, DD; Lyman, GH; Messersmith, WA; Michaud, LB; Miyata, SC; Robbins, A; Tallman, MS; Vadhan-Raj, S; Westervelt, P; Wong, MK; National Comprehensive Cancer Network (NCCN). Myeloid growth factors. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2007;5:188-202.
(2007)
Abstract
Djulbegovic, B; Hozo, I; Lyman, GH. Estimating net benefits and harms of screening mammography in women age 40 to 49 years. Annals of Internal Medicine. 2007;147:882.
(2007)
Abstract
Griggs, JJ; Culakova, E; Sorbero, ME; Poniewierski, MS; Wolff, DA; Crawford, J; Dale, DC; Lyman, GH. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. Journal of Clinical Oncology. 2007;25:2522-2527.
(2007)
Abstract
Griggs, JJ; Culakova, E; Sorbero, ME; van Ryn, M; Poniewierski, MS; Wolff, DA; Crawford, J; Dale, DC; Lyman, GH. Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. Journal of Clinical Oncology. 2007;25:277-284.
(2007)
Abstract
Huston, A; Lyman, GH. Agents under investigation for the treatment and prevention of neutropenia. Expert Opinion on Investigational Drugs. 2007;16:1831-1840.
(2007)
Abstract
Khorana, AA; Francis, CW; Culakova, E; Kuderer, NM; Lyman, GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110:2339-2346.
(2007)
Abstract
Khorana, AA; Francis, CW; Culakova, E; Kuderer, NM; Lyman, GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. Journal of Thrombosis and Haemostasis. 2007;5:632-634.
(2007)
Abstract
Kuderer, NM; Dale, DC; Crawford, J; Lyman, GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. Journal of Clinical Oncology. 2007;25:3158-3167.
(2007)
Abstract
Kuderer, NM; Khorana, AA; Lyman, GH; Francis, CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer. 2007;110:1149-1161.
(2007)
Abstract
Lyman, GH. ASCO Clinical Practice Guidelines and Beyond. Journal of Oncology Practice. 2007;3:330-331.
(2007)
Abstract
Lyman, GH. Economics of cancer care. Journal of Oncology Practice. 2007;3:113-114.
(2007)
Abstract
Lyman, GH. Editorial: gene expression profile assays as an aid in treatment decision making in early-stage breast cancer. Journal of Oncology Practice. 2007;3:187-188.
(2007)
Abstract
Lyman, GH; Cosler, LE; Kuderer, NM; Hornberger, J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer. 2007;109:1011-1018.
(2007)
Abstract
Lyman, GH; Khorana, AA; Falanga, A; Clarke-Pearson, D; Flowers, C; Jahanzeb, M; Kakkar, A; Kuderer, NM; Levine, MN; Liebman, H; Mendelson, D; Raskob, G; Somerfield, MR; Thodiyil, P; Trent, D; Francis, CW; American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. Journal of Clinical Oncology. 2007;25:5490-5505.
(2007)
Abstract
Lyman, GH; Kleiner, JM. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. Journal of the National Comprehensive Cancer Network : JNCCN. 2007;5:217-228.
(2007)
Abstract
Lyman, GH; Shayne, M. Granulocyte colony-stimulating factors: finding the right indication. Current Opinion in Oncology. 2007;19:299-307.
(2007)
Abstract
Pinto, L; Liu, Z; Doan, Q; Bernal, M; Dubois, R; Lyman, G. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Current Medical Research and Opinion. 2007;23:2283-2295.
(2007)
Abstract
Shayne, M; Culakova, E; Poniewierski, MS; Wolff, D; Dale, DC; Crawford, J; Lyman, GH. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer. 2007;110:1611-1620.
(2007)
Abstract
Tang, P; Hajdu, SI; Lyman, GH. Ductal carcinoma in situ: a review of recent advances. Current Opinion in Obstetrics and Gynecology. 2007;19:63-67.
(2007)
Abstract
